关键信息
-
基因名
IL18BP
- 应用
-
别名
IL18BP;Interleukin-18-binding Protein
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O95998
-
表达区间
31-194aa
-
氨基酸序列
ADPTPVSQTTTAATASVRSTKDPCPSQPPVFPAAKQCPALEVTWPEVEVP LNGTLSLSCVACSRFPNFSILYWLGNGSFIEHLPGRLWEGSTSRERGSTG TQLCKALVLEQLTPALHSTNFSCVLVDPEQVVQRHVVLAQLWAGLRATLP PTQEALPSSHSSPQQQGLEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HHHHHH
-
分子量
45 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
IL-18 binding protein (IL-18BP) is a crucial regulatory protein that modulates the activity of interleukin-18 (IL-18), a pro-inflammatory cytokine involved in various immune responses. Elevated IL-18 levels have been associated with several inflammatory and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and psoriasis, highlighting the need for effective therapeutic strategies to regulate its activity. IL-18BP acts by binding to IL-18, preventing it from interacting with its receptor and, consequently, inhibiting IL-18-mediated signaling pathways. This modulation is pivotal in controlling excessive inflammation and tissue damage. The recombinant form of IL-18BP has garnered significant attention in recent years as a potential therapeutic agent due to its ability to mitigate inflammatory responses in preclinical models. Researchers have been investigating its efficacy in various pathological contexts, focusing on its role in improving outcomes in diseases characterized by dysregulated IL-18 signaling. Understanding the structure-function relationship of IL-18BP and exploring its application in combination therapies may pave the way for novel anti-inflammatory treatments. Additionally, studies have been focusing on optimizing recombinant production methods to enhance yield and biological activity, further supporting its development as a therapeutic protein. Overall, IL-18BP represents a promising avenue for therapeutic intervention in diseases driven by IL-18-mediated inflammation, opening new possibilities for managing chronic inflammatory conditions.
